XML 20 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Cash flows from operating activities    
Net loss $ (363,806) $ (173,899)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities [Abstract]    
Depreciation and amortization 31,088 22,903
Non-cash operating lease expense 4,295 2,446
Non-cash finance lease amortization expense 41,382 0
Non-cash royalty revenue related to sale of future royalties (299) 0
Non-cash interest expense on liability related to sale of future royalties 14,557 0
Change in valuation of deferred and contingent consideration 16,980 35,960
Settlement of deferred and contingent consideration 10,613 0
Non-cash stock consideration, acquisition 42,869 0
Unrealized gain on equity investment (852) (2,529)
Unrealized gain on ClearPoint convertible debt security (633) 0
Non-cash interest expense 16,678 6,583
Loss on disposal of asset 25 0
Amortization of discounts on investments, net (559) (1,374)
Amortization of debt issuance costs 766 434
Share-based compensation expense 48,909 30,668
Unrealized foreign currency transaction (gains) losses, net (27,077) 205
Changes in operating assets and liabilities:    
Inventory, net 390 (1,574)
Prepaid expenses and other current assets (9,289) (11,771)
Trade receivables, net 121 5,879
Deposits and other assets (217) (1,073)
Accounts payable and accrued expenses 54,390 695
Other liabilities (4,096) (3,567)
Deferred revenue (5,940) 1,581
Net cash used in operating activities (129,705) (88,433)
Cash flows from investing activities    
Purchases of fixed assets (11,491) (9,104)
Purchase of convertible debt security (10,000) 0
Purchases of marketable securities (1,006,946) (239,386)
Sale and redemption of marketable securities 700,627 114,500
Acquisition of product rights and licenses (25,618) (20,250)
Purchase of equity investment 0 (4,000)
Net cash provided by (used in) investing activities (353,428) (158,240)
Cash flows from financing activities    
Proceeds from issuance of convertible notes 0 279,571
Proceeds from exercise of options 32,987 12,195
Termination and exit fees related to payoff of secured term loan (597) 0
Net proceeds from public offerings 28,092 324,262
Repayment of senior secured term loan (28,333) (6,667)
Payments on deferred consideration obligation (38,100) 0
Proceeds from employee stock purchase plan 2,406 1,564
Payment of finance lease principal (17,829) 0
Cash consideration received from Royalty Purchase Agreement 650,000 0
Net cash provided by financing activities 628,626 610,925
Effect of exchange rate changes on cash 449 (2,673)
Net decrease in cash and cash equivalents 145,942 361,579
Cash and cash equivalents, and restricted cash beginning of period 295,528 169,498
Cash and cash equivalents, and restricted cash end of period 441,470 531,077
Supplemental disclosure of cash information    
Cash paid for interest 9,802 7,042
Cash paid for income taxes 1,562 1,931
Supplemental disclosure of non-cash investing and financing activity    
Unrealized gain on marketable securities, net of tax 1,639 435
Right-of-use assets obtained in exchange for operating lease obligations 76,657 16,120
Right-of-use assets obtained in exchange for finance lease obligations 41,382 0
Acquisition of product rights and licenses 13,786 7,432
Issuance of common stock related to rights exchange 150,528 0
Accrued transaction costs related to public offerings 0 506
Accrued transaction costs related to issuance of convertible notes $ 0 $ 298